158 related articles for article (PubMed ID: 16760797)
1. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques.
Kinman L; Bui T; Larsen K; Tsai CC; Anderson D; Morton WR; Hu SL; Ho RJ
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):155-61. PubMed ID: 16760797
[TBL] [Abstract][Full Text] [Related]
2. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques.
Kinman L; Brodie SJ; Tsai CC; Bui T; Larsen K; Schmidt A; Anderson D; Morton WR; Hu SL; Ho RJ
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):387-97. PubMed ID: 14615656
[TBL] [Abstract][Full Text] [Related]
3. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.
Freeling JP; Koehn J; Shu C; Sun J; Ho RJ
AIDS Res Hum Retroviruses; 2015 Jan; 31(1):107-14. PubMed ID: 25402233
[TBL] [Abstract][Full Text] [Related]
4. Feasibility of weekly HIV drug delivery to enhance drug localization in lymphoid tissues based on pharmacokinetic models of lipid-associated indinavir.
Snedecor SJ; Sullivan SM; Ho RJ
Pharm Res; 2006 Aug; 23(8):1750-5. PubMed ID: 16832614
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles.
Endsley AN; Ho RJ
J Acquir Immune Defic Syndr; 2012 Dec; 61(4):417-24. PubMed ID: 22743598
[TBL] [Abstract][Full Text] [Related]
6. Lymphoid tissue targeting of anti-HIV drugs using liposomes.
Désormeaux A; Bergeron MG
Methods Enzymol; 2005; 391():330-51. PubMed ID: 15721390
[TBL] [Abstract][Full Text] [Related]
7. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy.
Bernard L; Peytavin G; Vuagnat A; de Truchis P; Perronne C
Lancet; 1998 Nov; 352(9142):1757-8. PubMed ID: 9848361
[No Abstract] [Full Text] [Related]
8. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus.
Kline MW; Fletcher CV; Harris AT; Evans KD; Brundage RC; Remmel RP; Calles NR; Kirkpatrick SB; Simon C
J Pediatr; 1998 Mar; 132(3 Pt 1):543-6. PubMed ID: 9544920
[TBL] [Abstract][Full Text] [Related]
9. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
Wong JK; Günthard HF; Havlir DV; Zhang ZQ; Haase AT; Ignacio CC; Kwok S; Emini E; Richman DD
Proc Natl Acad Sci U S A; 1997 Nov; 94(23):12574-9. PubMed ID: 9356491
[TBL] [Abstract][Full Text] [Related]
10. Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
McConnachie LA; Kinman LM; Koehn J; Kraft JC; Lane S; Lee W; Collier AC; Ho RJY
J Pharm Sci; 2018 Jul; 107(7):1787-1790. PubMed ID: 29548975
[TBL] [Abstract][Full Text] [Related]
11. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
Fletcher CV; Anderson PL; Kakuda TN; Schacker TW; Henry K; Gross CR; Brundage RC
AIDS; 2002 Mar; 16(4):551-60. PubMed ID: 11872998
[TBL] [Abstract][Full Text] [Related]
12. Low-doses of indinavir boosted with ritonavir in HIV-infected Thai patients: pharmacokinetics, efficacy and tolerability.
Cressey TR; Leenasirimakul P; Jourdain G; Tod M; Sukrakanchana PO; Kunkeaw S; Puttimit C; Lallemant M
J Antimicrob Chemother; 2005 Jun; 55(6):1041-4. PubMed ID: 15883177
[TBL] [Abstract][Full Text] [Related]
13. Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques.
Ho RJ; Larsen K; Bui T; Wang XY; Herz AM; Sherbert C; Finn E; Nosbisch C; Schmidt A; Anderson D; Agy M; Morton WR; Unadkat JD
J Acquir Immune Defic Syndr; 2000 Oct; 25(2):140-9. PubMed ID: 11103044
[TBL] [Abstract][Full Text] [Related]
14. Mechanism-based pharmacokinetic (MBPK) models describe the complex plasma kinetics of three antiretrovirals delivered by a long-acting anti-HIV drug combination nanoparticle formulation.
Kraft JC; McConnachie LA; Koehn J; Kinman L; Sun J; Collier AC; Collins C; Shen DD; Ho RJY
J Control Release; 2018 Apr; 275():229-241. PubMed ID: 29432823
[TBL] [Abstract][Full Text] [Related]
15. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
17. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
[TBL] [Abstract][Full Text] [Related]
18. Oral delivery of indinavir using mPEG-PCL nanoparticles: preparation, optimization, cellular uptake, transport and pharmacokinetic evaluation.
Kurd M; Sadegh Malvajerd S; Rezaee S; Hamidi M; Derakhshandeh K
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2123-2133. PubMed ID: 31155961
[No Abstract] [Full Text] [Related]
19. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
20. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.
Shen A; Zink MC; Mankowski JL; Chadwick K; Margolick JB; Carruth LM; Li M; Clements JE; Siliciano RF
J Virol; 2003 Apr; 77(8):4938-49. PubMed ID: 12663799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
